Search | Clinical Trials Finder

Conditions: Breast Neoplasms
Interventions: 9 Peptides from Her-2/neu, CEA, & CTA; Biological
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12, tyrosinase peptide; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 2
States / cities: Duarte, California • Los Angeles, California

Conditions: Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)
Interventions: WT1:126-134, PR1:169-177 Peptide, GM-CSF (Sargramostim), Montanide adjuvant; Biological · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Stage IV Breast Cancer
Interventions: Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG; Biological
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Glioblastoma (GBM)
Interventions: BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Temozolomide (TMZ), Losartan and aspirin; Drug
Lead sponsor: BreakBio Corp; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lung Cancer
Interventions: EP-2101, incomplete Freund's adjuvant; Biological
Lead sponsor: Epimmune; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 9
States / cities: Ocoee, Florida • Albany, New York • Durham, North Carolina + 6 more

Conditions: Liver Cancer
Interventions: AFP gene hepatocellular carcinoma vaccine; Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Melanoma (Skin)
Interventions: NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure; Biological · Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 16 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Stage IV Melanoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, Recurrent Melanoma
Interventions: flt3 ligand, gp100 antigen, MART-1 antigen, Montanide ISA-51, tyrosinase peptide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Timeline: 1998 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colo-rectal Cancer
Interventions: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine, Leucovorin, Oxaliplatin, Fluorouracil, Bevacizumab, Irinotecan, Cetuximab, Metastasectomy, Biospecimen collection, Computed Tomography, Panitumumbab; Biological · Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions: basiliximab, WT1 126-134 peptide vaccine, Montanide ISA 51 VG, poly ICLC, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: ALVAC(2)120(B,MN)GNP (vCP1452), HIV-1 Immunogen; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 9
States / cities: Los Angeles, California • Miami, Florida • Baltimore, Maryland + 5 more

Conditions: Nonneoplastic Condition
Interventions: E1M184V peptide vaccine, incomplete Freund's adjuvant, sargramostim, immunoenzyme technique; Biological · Other
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer
Interventions: Intracel KLH Vaccine, Biosyn KLH, Montanide ISA51, Tetanus toxoid; Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
Interventions: Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803, Ventana PD-L1 (SP263 or SP142) assay; Biological · Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: ipilimumab, Tyrosinase/gp100/MART-1 Peptides; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, HIV-1 Immunogen, Nelfinavir mesylate; Drug · Biological
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 13 Years and older
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Diego, California

Conditions: Prostate Cancer Recurrent
Interventions: RV001V, Placebo; Biological · Other
Lead sponsor: RhoVac APS; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Clearwater, Florida • Towson, Maryland • Omaha, Nebraska + 4 more

Conditions: Recurrent Melanoma, Stage IV Melanoma
Interventions: tyrosinase peptide, MART-1:27-35 peptide vaccine, gp100 antigen, incomplete Freund's adjuvant, sargramostim, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Melanoma (Skin)
Interventions: incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim, tetanus toxoid helper peptide, dimethyl sulfoxide, imiquimod, adjuvant therapy; Biological · Drug · Procedure
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 12 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Leukemia
Interventions: PR1 leukemia peptide vaccine, sargramostim, placebo; Biological · Other
Lead sponsor: The Vaccine Company; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 15
States / cities: Scottsdale, Arizona • Los Angeles, California • South San Francisco, California + 10 more

Conditions: Ovarian Neoplasm
Interventions: aldesleukin, incomplete Freund's adjuvant, p53 peptide vaccine, sargramostim, therapeutic autologous dendritic cells, in vitro-treated peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma (Skin)
Interventions: aldesleukin, incomplete Freund's adjuvant, sargramostim, tyrosinase peptide, tyrosinase-related protein-1; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Extraocular Extension Melanoma, Recurrent Intraocular Melanoma
Interventions: gp100 antigen, interleukin-2, MART-1 antigen, Montanide ISA-51; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Vaccination of High Risk Breast Cancer Patients

Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Vaccine Therapy in Treating Patients With Liver Cancer

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission

Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452

Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV

Vaccination With Tetanus and KLH to Assess Immune Responses.

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission

p53 Vaccine for Ovarian Cancer

Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye